Posted: 04/15/2025 03:18 am
TransMedics Group, Inc. (NASDAQ: TMDX), a leader in developing organ transplant technologies, finds itself in the spotlight not just for its innovative contributions but also for recent legal entanglements. The company's executive compensation details have drawn attention in the context of an ongoing class action lawsuit alleging securities law violations.
Among its executives, Stephen Gordon, the former Chief Financial Officer, is one of the highest earners. In 2024, his compensation package totaled $6,764,562. This included a salary of $470,769, stock awards valued at $1,825,608, option awards amounting to $2,792,805, and $572,400 from an incentive plan. Additionally, he received $1,102,980 categorized under all other compensation[^1^]. Gordon's 2020 compensation showed a stark contrast with a total of $917,826, comprising a salary of $370,510 and a bonus of $141,831[^2^].
In comparison, the current President and CEO, Waleed Hassanein, M.D., earned a total compensation of $6,758,070 in 2023. His earnings consisted of a salary of $633,846, stock awards worth $2,467,645, and option awards valued at $2,472,929[^3^]. This robust compensation aligns with the company’s performance metrics during his leadership term.
TMDX's performance on the stock market has been turbulent. As of the latest reports, the stock traded at $86.84, with a significant change of 7.77% from the previous close[^4^]. This market volatility is coupled with recent legal challenges. Several law firms have filed a class action lawsuit against TransMedics Group, alleging potential violations of federal securities laws by the company and certain senior executives. Investors who suffered financial losses between February 28, 2023, and January 10, 2025, are being urged to join the lawsuit, with significant deadlines approaching[^5^][^6^].
The company now faces the dual challenge of managing its executive compensation schemes while addressing legal issues. With high-profile firms like Levi & Korsinsky and Bleichmar Fonti & Auld, LLP involved in the litigation, the scrutiny on TransMedics is intensifying[^7^][^8^].
As TransMedics approaches its earnings announcement on April 28, 2025, stakeholders will closely watch if these developments impact their strategic decisions and financial performance[^9^].
---
1. [2024 Compensation Data for Stephen Gordon](https://www.sec.gov/Archives/edgar/data/1756262/000119312525077974/0001193125-25-077974-index.htm)
2. [2020 Compensation Data for Stephen Gordon](https://www.sec.gov/Archives/edgar/data/1756262/000119312523099159/0001193125-23-099159-index.htm)
3. [2023 Compensation Data for Waleed Hassanein](https://www.sec.gov/Archives/edgar/data/1756262/000119312524091873/0001193125-24-091873-index.htm)
4. Current Market Snapshot of TransMedics Group, Inc.
5. [Levi & Korsinsky Class Action Announcement](https://www.accessnewswire.com/newsroom/en/business-and-professional-services/shareholders-that-lost-money-on-transmedics-group-inc-tmdx-urged-1014821)
6. [Bleichmar Fonti & Auld Class Action Announcement](https://www.accessnewswire.com/newsroom/en/business-and-professional-services/tmdx-lawsuit-alert-levi-and-korsinsky-notifies-transmedics-group-1014675)
7. [Robbins Geller Rudman & Dowd LLP Investor Alert](https://www.bfalaw.com/cases-investigations/transmedics-group-inc)
8. [Pomerantz LLP Investor Alert](https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-transmedics-group-inc-of-class-action-lawsuit-and-upcoming-deadlines---tmdx-302427967.html)
9. [Announcement of Upcoming Earnings](NASDAQ)
